Talquetamab in relapsed/refractory multiple myeloma: Extended follow-up from MonumenTAL-1 and interventions for GPRC5D-related toxicities

home / between-the-lines / talquetamab-in-relapsed-refractory-multiple-myeloma-extended-follow-up-from-monumental-1-and

Panelists discuss extended follow-up data from the MonumenTAL-1 trial on talquetamab for relapsed/refractory multiple myeloma, highlighting its sustained efficacy and addressing strategies to manage GPRC5D-related toxicities associated with treatment.

Advanced Practice Decision-Making: Patient Selection and Baseline Assessment for Bispecific Therapies

EP. 1: Advanced Practice Decision-Making: Patient Selection and Baseline Assessment for Bispecific Therapies

Charise Gleason, MSN, NP-C, AOCNP ;Mariadela Matute, APRN, BMT-CN, AOCNP
July 16th 2025

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value as off-the-shelf options for patients post chimeric antigen receptor T-cell therapy or ineligible for it, and highlighting personalized treatment decisions based on prior therapies, antigen targets, infection risk, and emerging clinical evidence.

Introducing GPRC5D and MonumenTAL-1 Trial for R/R Multiple Myeloma

EP. 2: Introducing GPRC5D and MonumenTAL-1 Trial for R/R Multiple Myeloma

Charise Gleason, MSN, NP-C, AOCNP ;Mariadela Matute, APRN, BMT-CN, AOCNP
July 16th 2025

Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated patients and emphasizing the importance of managing unique keratin-related and neurologic toxicities linked to GPRC5D expression.